Showing 101–125 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Choi YH, Kang YA, Park KJ, Choi JC, Cho KG, et al.
Introduction This randomized, double-blind, placebo-controlled, phase 2a trial was conducted to evaluate the safety and immunogenicity of the ID93 + glucopyranosyl lipid adjuvant (GLA)-stable emulsion (SE) vaccine in human immunodeficiency virus (HIV)-negative, previously Bacillu…
Lesellier S, Birch CPD, Davé D, Dalley D, Gowtage S, et al.
Bovine tuberculosis (TB) in Great Britain adversely affects animal health and welfare and is a cause of considerable economic loss. The situation is exacerbated by European badgers ( Meles meles ) acting as a wildlife source of recurrent Mycobacterium bovis infection to cattle. V…
Milián-Suazo F, González-Ruiz S, Contreras-Magallanes YG, Sosa-Gallegos SL, Bárcenas-Reyes I, et al.
Bovine tuberculosis (bTB) is a disease of cattle that represents a risk to public health and causes severe economic losses to the livestock industry. Recently, one of the strategies recommended for reducing the prevalence of the disease in animals is the use of the BCG vaccine, a…
Manuja Gunasena, Rajni Kant Shukla, Naiquan Yao, Oscar Rosas Mejia, Michael D. Powell, et al.
Abstract The vaccine Mycobacterium bovis Bacillus Calmette–Guérin (BCG) elicits an immune response that is protective against certain forms of tuberculosis (TB); however, because BCG efficacy is limited it is important to identify alternative TB vaccine candidates. Recently, the …
GSK Clinical Trials
The purpose of this study is to assess the safety and immunogenicity of two doses of the TB vaccine administered according to a 0, 1 month schedule. In, addition, blood samples collected at different time points after vaccination will be analysed to see when exactly genes are act…
Ozdilek A, Paschall AV, Dookwah M, Tiemeyer M, Avci FY
Nucleic acid vaccines introduce the genetic materials encoding antigenic proteins into host cells. If these proteins are directed into the secretory pathway with a signal/leader sequence, they will be exposed to the host's glycosylation machinery, and, if their amino acid sequenc…
Bernatowska E, Skomska-Pawliszak M, Wolska-Kuśnierz B, Pac M, Heropolitanska-Pliszka E, et al.
Objectives The aim of the study was to estimate the rate of adverse reactions to live BCG Moreau vaccine, manufactured by Biomed in Poland, in severe combined immunodeficiency (SCID) patients. Material The profiles of 52 SCID patients vaccinated at birth with BCG, hospitalized in…
Gunasena M, Shukla RK, Yao N, Rosas Mejia O, Powell MD, et al.
The vaccine Mycobacterium bovis Bacillus Calmette-Guérin (BCG) elicits an immune response that is protective against certain forms of tuberculosis (TB); however, because BCG efficacy is limited it is important to identify alternative TB vaccine candidates. Recently, the BCG delet…
Greenblatt CL, Lathe R
…k, we provided a historical and molecular background to how vaccines, adjuvants, and their component molecules can elicit broad-spectrum protective effects against diverse agents, culminating in the development of the tuberculosis vaccine strain Bacille Calmette-Guérin (BCG) as a…
Vierboom MPM, Dijkman K, Sombroek CC, Hofman SO, Boot C, et al.
BCG vaccination can strengthen protection against pathogens through the induction of epigenetic and metabolic reprogramming of innate immune cells, a process called trained immunity. We and others recently demonstrated that mucosal or intravenous BCG better protects rhesus macaqu…
White AD, Sibley L, Gullick J, Sarfas C, Clark S, et al.
…h simian immunodeficiency virus (SIV) for the assessment of vaccines designed to prevent reactivation of TB. Following infection caused by aerosol exposure to an ultralow dose of Mycobacterium tuberculosis (M. tb), data trends indicated that subsequent coinfection with SIVmac32H …
Ishwarlall TZ, Okpeku M, Adeniyi AA, Adeleke MA
… unable to induce long-lasting protection. Various types of vaccines have been developed based specifically against M. ulcerans; however, to date, none has entered clinical trials or has been released for public use. Additional awareness and funding are needed for research in thi…
Anurag Bhargava
Nutrition is essential to survival, health, and protection from disease across the lifespan. In the 1970s, an adequate diet was described as the most effective vaccine available for respiratory, diarrheal, and other common infections, as nutritional supplementation reduced these …
Adepoju VA, Onyezue OI
…ases and 1.4 million deaths in 2020 alone, new and improved vaccines are urgently needed. Recent advancements in TB vaccine research offer hope, but a lack of funding, coordination and understanding of immune responses have impeded progress. A TB Vaccine Accelerator Council aims …
Dockrell HM, Butkeviciute E
The BCG vaccine will, in 2021, have been in use for 100 years. Much remains to be understood, including the reasons for its variable efficacy against pulmonary tuberculosis in adults. This review will discuss what has been learnt about the BCG vaccine in the last two decades, and…
Schaltz-Buchholzer F, Kjær Sørensen M, Benn CS, Aaby P
Background Following the introduction of oral Bacille Calmette-Guérin (BCG) a century ago, Albert Calmette suggested that BCG both provided protection against death from tuberculosis (TB) and other causes. The findings were not pursued. Today, there is considerable evidence that …
Wong NX, Buttery J, McMinn A, Azhar Z, Crawford NW
Bacille Calmete-Guerin vaccine is widely administered to reduce the risk of severe tuberculosis disease in children. Recent global vaccine supply issues have led to the use of alternative products, which may vary in side effect profile. We report on the safety of the Polish (More…
Liebler-Tenorio EM, Heyl J, Wedlich N, Figl J, Köhler H, et al.
…models to compare reactions to different mycobacteria or TB vaccines.
Stewart EL, Counoupas C, Quan DH, Wang T, Petrovsky N, et al.
…able protection; however, the development of more effective vaccines is hindered by a lack of defined correlates of protection (CoP) against M. tuberculosis . Pulmonary vaccine delivery is a promising strategy since it may promote lung-resident immune memory that can respond rapi…
Justiz Vaillant AA, Grella MJ
…unities alike. The gamut of diseases currently addressed by vaccines is extensive, encompassing diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps, rubella, pneumococcal pneumonia, smallpox, sepsis, meningitis, hepatitis B, varicella-zoster, tuberculosis, cholera, rota…
BioNTech Responsible Person
…ill evaluate four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule. Enrollment for BNT164a1 and BNT164b1 will be conducted independently, and in parallel. The trial will enroll participants di…
Michele Tameris, M.B.Ch.B.
The purpose of this study is to determine the safety, tolerability, and immunogenicity in BCG-vaccinated healthy adult subjects of an investigational vaccine being developed for the prevention of pulmonary tuberculosis.
Rappuoli R, Black S, Bloom DE
Most vaccines for diseases in low- and middle-income countries fail to be developed because of weak or absent market incentives. Conquering diseases such as tuberculosis, HIV, malaria, and Ebola, as well as illnesses caused by multidrug-resistant pathogens, requires considerable …
Kwon BE, Ahn JH, Park EK, Jeong H, Lee HJ, et al.
Early secretory antigenic target-6 (ESAT6) is a potent immunogenic antigen expressed in Mycobacterium tuberculosis as well as in some non-tuberculous mycobacteria (NTM), such as M. kansasii . M. kansasii is one of the most clinically relevant species of NTM that causes mycobacter…
Roces CB, Hussain MT, Schmidt ST, Christensen D, Perrie Y
…(lungs) have been considered for the development of subunit vaccines. Inert delivery systems such as poly (lactic-co-glycolic acid) (PLGA) are an interesting approach due to its approval for human use. However, PLGA suffers hydrolytic degradation when stored in a liquid environme…